Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 16;106(8):2161–2169. doi: 10.3324/haematol.2020.261859

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright© 2021 Ferrata Storti Foundation

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

PMC Copyright notice

Figure 1. — Box-and-whisker plots showing the effect of intravenous bevacizumab on hematologic parameters and epistaxis severity. A box represents the median and interquartile range and tails represent minimum and maximum values. Numbers at each time-point reflect the number of hereditary hemorrhagic telangiectasia (HHT) patients in a given analysis treated for at least that duration with complete data. (A) Effect on hemoglobin in HHT patients with baseline anemia (n=185). (B) Effect on Epistaxis Severity Score in patients treated for epistaxis (n=146). (C) Effect on red blood cell (RBC) transfusions in patients receiving transfusion in the 6 months prior to bevacizumab initiation (n=137). (D) Effect on iron infusion events in patients receiving intravenous iron in the 6 months prior to bevacizumab initiation (n=155). RBC: red blood cell; Mo: months; Tx: treatment.